HSBC has cut the target price on Biocon Ltd. from Rs 400 to Rs 390, as it sees negative impact on earnings per share due to the company's Rs 4,500-crore qualified institutional placement that ...

In a filing to the stock exchange, Biocon stated, "The U.S. Food and Drug Administration (USFDA) concluded a GMP inspection of our API facility (Site 6), located at Visakhapatnam, Andhra Pradesh ...

Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the United States Court of Appeals for the Federal Circuit (USCAFC) of patent US11084865 ('865 ...

Biocon and Eris have expanded a previous agreement, with Biocon selling Indian branded formulations businesses to Mumbai-based Eris for $150M.

Biocon Ltd expects its overall revenue to grow in mid-teens this financial year, and the company is betting on a robust launch pipeline in its generics as well as biosimilars businesses to drive ...

Biocon Group’s board is setting up a committee to evaluate strategic restructuring options, including a merger of its biosimilars arm Biocon Biologics Ltd with its flagship Biocon Ltd.

Shares of Biocon tumbled over 2 percent on June 18 after the US Food and Drug Administration issued three observations for its Active Pharmaceutical Ingredients (API) facility in Visakhapatnam ...

Biocon gets 4 observations from USFDA for Andhra facility The US Food and Drug Administration (USFDA) concluded a GMP inspection of the company's API facility (Site 5), located at Visakhapatnam ...

Biocon gets 4 observations from USFDA for Andhra Pradesh facility The US Food and Drug Administration (USFDA) concluded a GMP inspection of the company's API facility (Site 5), located at ...